Neha Motwani Elected to Longeveron® Board of Directors
July 09, 2024 09:00 ET
|
Longeveron
Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
July 08, 2024 09:00 ET
|
Longeveron
Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.
Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction
June 18, 2024 16:48 ET
|
Longeveron
Longeveron raises $4.4 Million in gross proceeds from warrant exercise transaction to fund development of its cellular therapy Lomecel-B
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
June 17, 2024 09:00 ET
|
Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds
June 17, 2024 08:38 ET
|
Longeveron
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds
Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease
June 11, 2024 09:00 ET
|
Longeveron
Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024
June 10, 2024 09:00 ET
|
Longeveron
Longeveron to Present at the Emerging Growth Virtual Conference
Longeveron® Announces Contract Development and Manufacturing Business and First Contract
June 03, 2024 09:00 ET
|
Longeveron
Longeveron launches contract development and manufacturing business for stem cell therapies. 15,000 sf state-of-the-art GMP facility with 8 cleanrooms.
Longeveron® to Attend BIO International Convention 2024
May 28, 2024 08:05 ET
|
Longeveron
Longeveron to attend BIO 2024, exploring potential partnership and strategic opportunities for its Alzheimer’s disease program.
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET
|
Longeveron
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.